Investigating the Role of BAFF and Its Receptors in Renal Transplant Recipients with Chronic Antibody-Mediated Rejection

Background Kidney transplantation is the best treatment option for end stage renal disease (ESRD), but graft rejection is still a big obstacle that occurs in spite of immunosuppressive therapy. B cells are considered as the major reason for renal graft rejection because of antibody production. Due to their roles in B cell function, we intended to evaluate the B cell activating factor (BAFF) and its receptors including BAFF receptor (BAFF-R), B cell maturation antigen (BCMA), and transmembrane activator and cyclophilin ligand interactor (TACI) in renal transplant patients. Method The study included 40 kidney allograft patients with cAMR, 40 stable kidney allograft patients, and 8 healthy volunteers with normal kidney function. The percentage and absolute number of CD19+ B cells were analyzed by flow cytometry, the serum level of BAFF was analyzed by ELISA, and mRNA expressions of BAFF and BAFF receptors (BAFF-R, BCMA, and TACI) were measured using quantitative real-time PCR. Results The percentage and the absolute number of B cells decreased significantly in stable and cAMR patients compared to healthy individuals. The serum level and gene expression of BAFF, as well as the mRNA level of BCMA, were increased significantly in both cAMR and stable patients compared to healthy volunteers. There was an overexpression of TACI mRNA in cAMR patients compared to stable patients. Conclusions Both soluble protein and mRNA transcript of BAFF increased in transplant recipients. However, BAFF neither at the serum level nor at the mRNA transcript level cannot be a good biomarker for the prediction of cAMR. In addition, expression of TACI, compared to other receptors of BAFF, confers a potential to be used in distinguishing cAMR and stable kidney transplant patients.

[1]  A. Amirzargar,et al.  B cell modulation strategies in the improvement of transplantation outcomes. , 2020, Molecular immunology.

[2]  A. Keshtkar,et al.  Transitional immature regulatory B cells and regulatory cytokines can discriminate chronic antibody-mediated rejection from stable graft function. , 2020, International immunopharmacology.

[3]  K. E. Groeneweg,et al.  Presence of intragraft B cells during acute renal allograft rejection is accompanied by changes in peripheral blood B cell subsets , 2019, Clinical and experimental immunology.

[4]  A. Amirzargar,et al.  Interferon regulatory factors: Where to stand in transplantation. , 2018, Transplant immunology.

[5]  D. Kamińska,et al.  B Cell Activating Factor (BAFF) in Long-term Kidney Transplant Recipients Is Not a Prognostic Marker for Allograft Dysfunction or Survival. , 2018, Transplantation proceedings.

[6]  Haiyan Xu,et al.  B Cell Activating Factor, Renal Allograft Antibody-Mediated Rejection, and Long-Term Outcome , 2018, Journal of immunology research.

[7]  M. Suthanthiran,et al.  Urine biomarkers informative of human kidney allograft rejection and tolerance. , 2018, Human immunology.

[8]  A. Kribben,et al.  Pretransplant serum BAFF levels are associated with pretransplant HLA immunization and renal allograft survival. , 2017, Transplant immunology.

[9]  W. Stohl.  Inhibition of B cell activating factor (BAFF) in the management of systemic lupus erythematosus (SLE) , 2017, Expert review of clinical immunology.

[10]  F. Claas,et al.  B Cell Immunity in Solid Organ Transplantation , 2017, Front. Immunol..

[11]  A. Koenig,et al.  Lymphoid Neogenesis and Tertiary Lymphoid Organs in Transplanted Organs , 2016, Front. Immunol..

[12]  B. Chung,et al.  Clinical Significance of Pre- and Post-Transplant BAFF Levels in Kidney Transplant Recipients , 2016, PloS one.

[13]  L. E. Becker,et al.  Immune mechanisms of acute and chronic rejection. , 2016, Clinical biochemistry.

[14]  D. Isenberg,et al.  Exploring BAFF: its expression, receptors and contribution to the immunopathogenesis of Sjögren's syndrome. , 2016, Rheumatology.

[15]  Geetha Chalasani,et al.  B Cells, Antibodies, and More. , 2015, Clinical journal of the American Society of Nephrology : CJASN.

[16]  X. He,et al.  Serum miR-338-5p, soluble B-cell-activating factor, allo-antibodies, and renal transplantation. , 2015, Transplantation proceedings.

[17]  S. Knechtle,et al.  Neutralizing BAFF/APRIL With Atacicept Prevents Early DSA Formation and AMR Development in T Cell Depletion Induced Nonhuman Primate AMR Model , 2015, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[18]  B. Chung,et al.  Current Issues in the Treatment of Chronic Antibody-Mediated Rejection in Kidney Transplantation , 2014 .

[19]  Simon A. Jones,et al.  Ectopic lymphoid-like structures in infection, cancer and autoimmunity , 2014, Nature Reviews Immunology.

[20]  J. Jais,et al.  Peripheral B-Cell Phenotype and BAFF Levels are Associated With HLA Immunization in Patients Awaiting Kidney Transplantation , 2014, Transplantation.

[21]  J. Pers,et al.  B cells display an abnormal distribution and an impaired suppressive function in patients with chronic antibody-mediated rejection. , 2014, Kidney international.

[22]  M. Clatworthy,et al.  Elevated Pretransplantation Soluble BAFF Is Associated With an Increased Risk of Acute Antibody-Mediated Rejection , 2013, Transplantation.

[23]  M. Haas.  Pathology of C4d-negative antibody-mediated rejection in renal allografts , 2013, Current opinion in organ transplantation.

[24]  Ş. Yıldız,et al.  Comparison of tacrolimus with a cyclosporine microemulsion for immunosuppressive therapy in kidney transplantation. , 2013, Turkish journal of urology.

[25]  S. Brouard,et al.  BAFF and BAFF‐R Levels Are Associated With Risk of Long‐Term Kidney Graft Dysfunction and Development of Donor‐Specific Antibodies , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[26]  M. Kemper,et al.  Elevated serum levels of B-cell activating factor in pediatric renal transplant patients , 2012, Pediatric Nephrology.

[27]  J. Ritz,et al.  Recovery of B-cell homeostasis after rituximab in chronic graft-versus-host disease. , 2011, Blood.

[28]  C. Gluud,et al.  Tacrolimus versus cyclosporine as primary immunosuppression after heart transplantation: systematic review with meta-analyses and trial sequential analyses of randomised trials , 2010, European Journal of Clinical Pharmacology.

[29]  E. Reed,et al.  Effect of Antibodies on Endothelium , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[30]  G. Jhangri,et al.  Endothelial Gene Expression in Kidney Transplants with Alloantibody Indicates Antibody‐Mediated Damage Despite Lack of C4d Staining , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[31]  R. Eming,et al.  Rituximab mediates a strong elevation of B-cell-activating factor associated with increased pathogen-specific IgG but not autoantibodies in pemphigus vulgaris. , 2009, The Journal of investigative dermatology.

[32]  X. He,et al.  The expression of B-cell activating factor belonging to tumor necrosis factor superfamily (BAFF) significantly correlated with C4D in kidney allograft rejection. , 2009, Transplantation proceedings.

[33]  Haiyan Xu,et al.  The Abnormal High Expression of B Cell Activating Factor Belonging to TNF Superfamily (BAFF) and Its Potential Role in Kidney Transplant Recipients , 2008, Cellular and Molecular Immunology.

[34]  J. Michel,et al.  B Cell Survival in Intragraft Tertiary Lymphoid Organs After Rituximab Therapy , 2008, Transplantation.

[35]  E. Lefèvre,et al.  BAFF enhances chemotaxis of primary human B cells: a particular synergy between BAFF and CXCL13 on memory B cells. , 2008, Blood.

[36]  D. Isenberg,et al.  B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response. , 2008, Annals of the rheumatic diseases.

[37]  X. Mariette,et al.  Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production , 2006, Annals of the rheumatic diseases.

[38]  P. Schneider,et al.  BAFF, APRIL and their receptors: structure, function and signaling. , 2006, Seminars in immunology.

[39]  D. Hilbert,et al.  Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse. , 2006, Arthritis and rheumatism.

[40]  J. Michel,et al.  Lymphoid neogenesis in chronic rejection: evidence for a local humoral alloimmune response. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[41]  U. Kunzendorf,et al.  Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[42]  M. Scott,et al.  BAFF binding to T cell‐expressed BAFF‐R costimulates T cell proliferation and alloresponses , 2004, European journal of immunology.